SWOG clinical trial number
CTSU/NRG-BR007

A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer

Open
Phase
Abbreviated Title
Ph III Evaluation of De-escalation of Radiation for Stage I, Hormone Sensitive HER2-, Treatment of Stage I, Hormone Sensitive, HER2- Oncotype Recurrence Score </=18
Status Notes
CTSU/NRG-BR007 has been endorsed and activated by SWOG, effective 6/15/2021. CTSU/NRG-BR007 was activated by NRG Oncology, effective 6/7/21.
Activated
06/07/2021

Research committees

Breast Cancer

Other Clinical Trials

S2206
SWOG Clinical Trial Number

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer

Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
15% Accrual
Accrual
15%
Open
Phase
S2212
SWOG Clinical Trial Number

TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)

Research Committee(s)
Breast Cancer
Activated
07/21/2023
23% Accrual
Accrual
23%
Open
Phase
CTSU/NRG-BR007
SWOG Clinical Trial Number

A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer

Research Committee(s)
Breast Cancer
Activated
06/07/2021
Open
Phase